702 Marshall St Suite 614
Redwood City, CA 94062
Backed by NIH grant funding and venture capital, and led by an ex-pharma, serial entrepreneur management team, Trellis Bioscience utilizes its CellSpot platform to discover rare, naturally optimized antibodies in healthy donor blood against infectious diseases and cancer. These antibodies offer unique biological characteristics and are de-risked for drug development due to negligible toxicity arising from off-target binding. So far, the company has discovered four infectious disease drug candidates – each with demonstrated efficacy in model systems – including a novel antibody targeting multiple species of drug-resistant bacteria, antibodies targeting respiratory syncytial virus (RSV) and human cytomegalovirus (HCMV), and a pan-influenza antibody cocktail licensed to ContraFect Corporation in 2014. The Company has also successfully expanded its efforts into cancer immunotherapy by cloning high affinity anti-TIM-3 and anti-KIR antibodies from healthy human individuals.